Psoriasis is an immune-mediated skin disease with a genetic predisposition. There is an involvement of the interaction of adaptive and innate immunity, which is the main pathological mechanism in this disease. Cytokines, which are secreted, mediatethe interaction of the T cells with the cells of dendrites, keratinocytes, and macrophages [1]. Biologists over the past decade have developed and approved blockers for interleukinIL-23, tumour necrotic factor , and IL-17 for psoriasis treatment [2]. This disease is an immunesystems-related disease of joints and also of skin, which is recurrent, chronic, and common. It has a considerable huge negative impact on various aspects of an affected patient's health, like emotional, psychosocial, and physical well-being [2].
One of the main determinants of expression of the disease is the carriage of the HLA-Cw6 and environmental triggers such as beta-haemolytic infection caused by Streptococcus in the early stage of psoriasis, like if it begins before 40 years of age [3]. The cells that are antigen-presentingare present in the skin and secrete the IL-12 and IL-23, which ultimately activate type 1 (Th1) and type 17 (Th17)T helper cells to produce a cellular type of immune response. The cutaneous findings which are observed in this disease are due to the development of a state of chronic inflammation, altered hyperproliferation of epidermis, apoptosis, differentiated mechanism, and neo-angiogenesis which is caused by different types of cytokines such as tumour necrosis factor (TNF) [4].
There can be dysfunction in the immune systems, particularly in autoimmune diseases, which are caused by specific triggers that vary among individuals. Whereas in psoriasis, it most commonly may include trauma of the skin, like bites of insects, scratches, and sunburn. Stress can also be considered as one of the triggers. An inflammatory response is accidentally generated in the activated immune systemin psoriasis. The immune system works against or attacks the healthy cells as if they resemble foreign invading harmful pathogens. Here, signalling molecules are produced in excess, as well as the helper variant of T type of lymphocytes or T kind of cells, which are the white cells of blood, that becomeirregularly active. The blood vessels present in the skinwidendue to the action of cytokine molecules. So thereafter, there will be an accumulation of keratinocytes and white blood cells, which will in turn make the outermost skin layer grow much quicker than the normal one. In the usual scenario, a person without psoriasis would take up to 3-4 weeks for cell maturation, migration to the skin surface, dividing, and also sloughing off, whereas in psoriasis, for the same events, it takes just 3-7 days. The outcome of this is that there is a thick skin buildup with flushed, scale, skin, and plaques.
Psoriasis begins in one-third of the overall cases in childhood itself and is of long duration. It is acommonly occurring inflammation-related disorder of the layer of skin that is immune-mediated [5]. For the exacerbation and onset of the disease, there are numerous factors: mutations in the gene 14 of the recruitment of the caspase domain of the family and the genetic factor which has the HLA-Cw6; environmental factors like medications, lifestyle; and infectious diseases [6].
Some triggers like injury to the skin or medications like lithium, quinidine, antimalarial drugs, infections, and stress, cause most kinds of psoriasis. Allergies, weather, and diet too can be the other triggers for this condition. There are about seven main kinds of psoriasis: plaque-type psoriasis; Guttatepsoriasis; inverse psoriasis; pustular psoriasis; erythrodermic psoriasis; nail psoriasis; and psoriatic arthritis.
While identifying this disease, we look for its symptoms, which can appear like rashes occurring in patches and lookdifferent as we see them in each individual. Some may appear as major eruptions all over the body or dandruff-like scaling. It could also be rashes with variation in the colours like shades of brown or pink or black skin or grey with purple or even with red along with silver scaling on the white skin, or cracked skin due to dryness that might bleed, or scaling small spots usually occurring in children, burning sensation, soreness, the appearance of episodic rashes that would aggravate for some weeks or months and then eventually subside.
As we mentioned earlier, among the various kinds of psoriasis, plaque is one. It causes raised patches of skin covering scales, itchiness, and dryness, and it is the most common kind of psoriasis. Scalp, knees area, elbow, and lower back are the frequent occurring sites. Depending on the colour of skin, there is variation in the colour of patches. Particularly on brown or black skins, there might be temporary changes due to postinflammatory hyperpigmentation in the appearance of colour as an outcome of the healing of the altered part of the layer of skin.
In the other kind, we see nail psoriasis which causes abnormally grown nails with discolouration and pitting affecting the fingernails and toenails. The nails could loosen up and get separated from the nail bed in this, also called onycholysis, and if it gets severe, then the nails may even crumble.
Further, there is also Guttate and inverse psoriasis, wherein the prior one mainly affects children and among adults and is mainly triggered by any infection caused due to Streptococcus,which is a bacterial infection. It is identified by scaling spots all over the trunk or arms, and legs, which are small drop-shaped. Inverse psoriasis is another kind in which there is an occurrence of inflamed skin which appears in smooth patchwork and worsens with sweating and friction, and it commonly acts on the folding of the skin of the area of the groinor buttocks and also of breasts. This kind of psoriasis is usually triggered by fungal infections.
The very least occurring kind of psoriasis is the erythrodermic type psoriasis which may either be chronic, which is of longer duration, or acute, which is of short duration. It appears like a peeling form of a rash that can itch or burn covering the entire body surface.
A rare kind which can be defined as blisters with pus is pustular psoriasis. It can appear in the small area of the sole and palm or like widespread patches. The most clearly demarcated are the generalized pustular, palmoplantar, and acrodermatitis continua of Hallopeau among pustular psoriasis which is a heterogenous entity of different organ disease subtypes clinically. These are different from psoriasis vulgaris in phenotype and genetic ways but these subtypes may resemble to plaque psoriasis, establishing the rationale for the inclusion in the psoriasis band. As shown by the recent identification of mutation of three different kinds of genes, of the skin's innate immune systems, the genetic background is thought to be monogenic which is unlikely in psoriasis, the genes are IL36RN, CARD14 and AP1S3 [7]. Paradoxical psoriasis form of dermatitis is usually triggered by subtypes of generalized pustularsand its various kinds like acute pustulosis, acrodermatitis, pustular of palmoplantar, and different kinds of pustular of mostly a TNF-blocker. Table 1 gives the types of psoriasis [8].
The pustular type of psoriasis may be present as the generalized type in the form of recurrent illness which is systemic, or as in palmoplantar type in the form of a locally centred disease mainly affecting the sole and palm, or in acrodermatitis in the nail beds or its digits. The consequences and severity should not be ignored or taken lightly, although these types of conditions are rare. With the capability of life-harming complications like a medical emergency of generalized pustular type of psoriasis when it appears like an acute episode like a flare. Debilitating conditions can be seen in the palmoplantar pustular type of psoriasis and in the acrodermatitis continua of Hallopeau. While in acrodermatitis there may be irreversible damage to the bone or nail, whereas in palmoplantar pustular psoriasis there is health-wise-related impaired life quality and morbidity psychiatrically [9].
Fever and malaise generally are accompanied by a systemic type of inflammatory, chronic disease, that is the generalized pustular type of psoriasis. Multiple pustules which are sterile occur all over the body surface along with diffused erythema and extremities swelled up, in generalized pustular psoriatic patients. There can behealth-threatening situations as generalized pustular often reoccur in the lifetime. Clinicians and researchers are being provided with major advances in the approach towards the pathomechanism of generalized pustular understanding with the help of the underlying genetic molecular basis of different cases with recent discoveries. Figure 1 give the types of pustular psoriasis [10].
The discovered anomalies include an unusual gain of the function of mutations in gene encoding around keratinocyte signalling molecule CARD14 and a loss-of-function mutation in the interleukin 36 receptor antagonist gene. Neutrophils and interleukin 36 (IL-36) are now recognised as key players in the pathogenesis of generalized pustular, with IL-36 signalling serving as a connecting link between the responses of innate and adaptive immune systems. Inflammation is now thought to be brought on by an aberrant innate immune response that is primarily genetically determined and results in an inflammatory kind of keratinization. Currently, generalized pustular is regarded as a representative of this newly discovered class of skin disorders known as autoinflammatory keratinization disease [11].
Retinoids, or methotrexate, or cyclosporine, also corticosteroids, or TNF-alpha inhibitors, topical therapy, and phototherapy are amongless well-established treatments. TNF-alpha inhibitors should be used in conjunction with methotrexate to prevent the development of antidrug antibodies [12].
Around 20% of patients referred to the early arthritis clinic have psoriatic arthritis, which is difficult to diagnose and treat. For the prevention of the function loss occurring long term and also to assure the best arthritis management and important comorbidities, early diagnosis is crucial. The differential diagnosis for a rheumatologist includes rheumatoid arthritis, also gout, including various inflammatorily arthritides. Once the condition has been identified, it is critical to thoroughly evaluate it, looking for signs of arthritis, or enthesitis, or dactylitis, or skin/nail disease, and also axial involvement [13].
Psoriatic arthritis is a chronic, autoimmune-mediated, inflammatory arthropathy that affects the joints and entheses, particularly those of the axial skeleton. It is associated with an increased risk of cardiovascular disease mortality [14].
Cytokine inhibitors, particularly those specific for tumour necrosis factor and, more recently, the interleukin 23-T-helper-17 cell pathway, have been very successful in the treatment of disease manifestations in a variety of tissues, even though targeting the interleukin 23-T-helper-17 cell pathway may be more effective in treating psoriasis than arthritis [14].In Western adults, it is prevalent at 2-4%, and psoriatic arthritis develops in 20-30% of psoriasis sufferers [15]. This illness affects several organ systems, including skin, nails, entheses, peripheral and axial joints, and nails. Osteoporosis, or uveitis, or subclinical intestinal inflammation, and also cardiovascular disease are all associated with psoriatic arthritis as comorbidities. Its heterogeneity has made diagnosis challenging. Here, we review its classification criteria in an updated manner. CASPAR, which stands for Classified Criteria for Psoriatic Arthritis, type of screening instruments are used to help in quick diagnosis, recent discoveries on aetiology, and new therapy modalities, which also include biological drugs [15].
Historically, non-steroidal anti-inflammatory drugs and the same old medicines that treat rheumatic diseases were used to treat psoriatic arthritis patients. Although their ability to halt the radiological development of joint disease is not established. Contrarily, anti-tumour necrotic factor medications such as certolizumab, or etanercept, or infliximab, or adalimumab, and also golimumab are considered in this aspect. Apremilast, an orally taken phosphodiesterase 4 inhibitor, tofacitinib, a Janus kinase inhibitor, and numerous new biologics that target the IL-23 and IL-17 pathways, such as secukinumab, or brodalumab, or ixekizumab, and also ustekinumab, are among the latest psoriatic arthritis medications [16].
Evidence suggests nutrition performs a significant aspect in the aetiology of psoriasis which is growing, among other psoriasis risk factors. In particular, diet, nutrition, and body weight may worsen or possibly start the disease's clinical signs [17]. There are a number of reasons that could account for the elevated frequency of cardiovascular events in the psoriasis population. The high prevalence of traditional cardiovascular risk factors and metabolic disorders are the main contributors to the significant cardiovascular burden in psoriasis patients. Similarly, the coexistence of systemic inflammation and metabolic disorders may raise the risk of cardiovascular disease in these people [18].
Psoriasis vulgaris is the most well-known and manageable human disease that is mediated by T lymphocytes and dendritic cells. Inflammatory myeloid dendritic cells release IL-23 and IL-12 to encourage IL-17-producing T cells, Th1 cells, and Th22 cells to produce significant amounts of the psoriatic cytokines IL-17, IFN (interferon), TNF, and IL-22 [19]. Patients with this genotype have been observed to have distinct clinical characteristics and acquire the disease at an earlier age, with a concordance of about 60% in monozygotic twins. HLA-Cw*0602 is a substantial risk factor for the beginning of the illness, and homozygous people are also at risk, according to recent linkage and higher resolution association studies.
Compared to heterozygotes, they have a disease risk that is around 2.5 times higher for this gene. According to published evidence, (cells of differentiation) CD8+ T cells may be a key effector in psoriasis. A notable characteristic of persistent psoriasis lesions is epidermal infiltration of oligoclonal CD8+ T cells, which are reacting to particular antigens, and likely also of CD4+ T cells in the dermis [20].
Local treatments, or phototherapies, and also systemic treatments like standard systemic therapy and biotherapy, are all currently available and, in the major part of the cases, are sufficient to control this skin condition. So as to improve these children's lifetime, subsequent management should concentrate on preserving therapeutic efficacy and preventing recurrence by minimising any of it [21].
Hydration of skin like frequent use of moisturisers and emollients, careful, and gentle skin cleaning, detection and avoidance oftriggers related to the phenomenon of Koebner like excoriation, maceration, and foci which are infectious are all important parts of treating psoriasis (Streptococcus pyogenes). Patients with psoriasis have shown that moisturisers considerably reduce their skin problems and enhance their quality of life. Due to the prevalence of dry skin, which increases the irritation of sick skin, they are an effective first-line treatment [22].
Newer topical treatments like calcipotriol and immunosuppressive medications like cyclosporin A and FK506 are significantly changing how psoriasis is treated [23]. Up until recently, corticosteroids, tars, anthralins, and keratolytics were the cornerstones of topical therapy. However, recently, topical retinoids, a novel anthralin preparation, and vitamin D analogues have increased doctors' treatment toolkits [24].
The topical management of psoriasis requires the use of emollients, moisturisers, and keratolytic medications. They serve as adjuvants to conventional therapies and aid in lowering the scale load of particular patients. Emollients and moisturisers primarily function to support proper hyperproliferation, or differentiation, and apoptosis; additionally, they have anti-inflammatory actions, for instance through physiologic lipids [25].
Upper respiratory tract infection is the most common reason for asthma in children. Treatment is determined based on the disease's severity and whether or not it has affected any joints. Corticosteroids and calcipotriene are examples of topical treatments. Systemic retinoids, ultraviolet radiation, and cyclosporine all reduce cutaneous psoriatic lesions. Both the cutaneous and joint symptoms of psoriasis respond well to methotrexate sodium and etanercept [26]. People with more severe, persistent, or extensive psoriasis can benefit from systemic medications, phototherapy, and other treatments. Although these treatments are more efficient than topical ones, they are also linked to serious cutaneous and systemic side effects [27].
UVB, that is ultraviolet B phototherapy, is a successful treatment for the widespread disease that allows for both quick management and long-term maintenance [28]. While cyclosporine is helpful, especially when used briefly in acute exacerbation situations, it should be substituted by other treatments for long-term maintenance [28].Lower concentrations and shorter durations of topical corticosteroids should be prescribed for treating children. Patients who are pregnant or nursing can benefit from topical corticosteroids in a safe and efficient manner. They are available in many different formulations, including shampoos, ointments, creams, lotions, gels, foams, and oils [29]. Although topical steroids are often used, there are only a few disorders that have been proved to benefit from their usage, such as psoriasis, vitiligo, eczema, atopic dermatitis, phimosis, acute radiation dermatitis, and lichen sclerosus [30].
The likelihood of psoriasis symptoms improving appears to be higher for foods and substances with systemic anti-inflammatory properties [31]. When combined with topical or systemic therapy, a low-calorie diet (LCD) improves the Dermatology Life Quality Index and Psoriasis Area and Severity Index. However, LCD was not successful in maintaining disease remission when patients stopped concurrent cyclosporine or methotrexate therapy [32]. Psoriasis patients usually have an imbalanced diet, with a higher consumption of fat and a lower intake of fish or dietary fibre, as compared to controls. Such dietary habits may have an impact on the frequency and intensity of psoriasis. Nutrition has an impact on the start, progression, and comorbidities of psoriasis [33].Body mass index and psoriasis severity have been linked in various studies, and obesity has been linked to a pro-inflammatory condition [34].
When it comes to the safety and effectiveness in patients having covid vaccine with immune-mediated inflammatory diseases (IMIDs), there is little reason to believe that these patients face any higher risk of negative side effects than healthy controls [35].Because of the elevated risk of infection, especially in high-risk areas, conventional immunosuppressive medications like methotrexate and cyclosporine, as well as anti-TNF drugs, should not be recommended. The side effect of hypertension, which has been linked to a higher likelihood of developing severe COVID-19 (coronavirus disease), may make using cyclosporine riskier. Given the lack of conclusive evidence to date that biologics increase the risk of COVID-19, these drugs should only be stopped when a patient displays COVID-19 symptoms [36].Due to the COVID-19 pandemic, clinicians treatingIMIDs, such as psoriasis, have encountered significant challenges. Patients with severe psoriasis are more likely to have obesity, hypertension, diabetes, and male sex as risk factors for severe COVID-19. The risk of severe infection is also known to increase with the use of several systemic psoriasis treatments. Therefore, it makes sense that in the early stages of the pandemic individuals receiving typical targeted systemic medication were believed to have a greater chance of getting a severe COVID-19 infection. In addition to risk-reducing behaviours like social distance suggested by the World Health Organization, people who were deemed to be more sensitive, such as those using immunosuppressants, were encouraged to adopt greater measures of social isolation [37]. The COVID-19 pandemic negatively affects the treatment of psoriasis and the provision of healthcare [38]. Patients with psoriasis who have had biological treatment or another sort of systemic therapy may develop a mild case of SARS-CoV-2(severe acute respiratory syndromecoronavirus 2) infection, while they may also briefly experience an aggravation of skin lesions [39].
Read more here:
Types of Psoriasis and Their Effects on the Immune System - Cureus
- Guselkumab Demonstrates Significant Improvement in Psoriasis Symptoms and HRQoL, Reduces Sexual Impairment ... - Dermatology Times - April 18th, 2024 [April 18th, 2024]
- Psoriasis Patients with Arthralgia At Increased Risk of Psoriatic Arthritis Development - MD Magazine - April 18th, 2024 [April 18th, 2024]
- Diagnosing Psoriatic Arthritis for the Dermatologist: Guidance From the Experts - Medscape - April 18th, 2024 [April 18th, 2024]
- Secukinumab 300 mg May Improve PsA or Active Psoriasis More Than 150 mg - MD Magazine - April 18th, 2024 [April 18th, 2024]
- The Impact of Pediatric Plaque Psoriasis on Children and Caregivers - HMP Global Learning Network - April 18th, 2024 [April 18th, 2024]
- Guselkumab Led to Improvements Over Several Psoriatic Arthritis Disease Domains - MD Magazine - April 18th, 2024 [April 18th, 2024]
- Dual Diagnosing and Managing Psoriasis and Psoriatic Arthritis - The Dermatologist - April 18th, 2024 [April 18th, 2024]
- Etanercept Effective for Psoriasis, Rheumatic Disease Among Patients Extending Treatment After 12-Weeks - MD Magazine - February 9th, 2024 [February 9th, 2024]
- High Response Rates in Psoriasis With Oral IL-23 Inhibitor - Medpage Today - February 9th, 2024 [February 9th, 2024]
- Psoriasis and eczema have complex causes and consequences that researchers are seeking to uncover - Medical Xpress - February 9th, 2024 [February 9th, 2024]
- New Hope in Treatment of Plaque Psoriasis: Study Shows Promising Results - Medriva - February 9th, 2024 [February 9th, 2024]
- No Difference in Psoriasis Immune Response Despite Switch Between AVT02, Adalimumab - MD Magazine - February 9th, 2024 [February 9th, 2024]
- Oral IL-23 Receptor Antagonist Peptide Effective in PASI Reduction for Psoriasis - MD Magazine - February 9th, 2024 [February 9th, 2024]
- Breakthrough in Psoriasis Treatment: JNJ-77242113 Shows Promising Results - Medriva - February 9th, 2024 [February 9th, 2024]
- Promising Results from Phase II Trial of Oral Interleukin Inhibitor for Psoriasis Treatment - Medriva - February 9th, 2024 [February 9th, 2024]
- Promising Results from the FRONTIER 1 Trial - An Exploration of JNJ-77242113 in the Treatment of Moderate-to ... - Medriva - February 9th, 2024 [February 9th, 2024]
- Personal Experience with Psoriatic Arthritis and Atopic Dermatitis - Medriva - February 9th, 2024 [February 9th, 2024]
- Rising Cost of Stelara: Impact on Patients and Johnson & Johnson's Market Performance - Medriva - February 9th, 2024 [February 9th, 2024]
- Global Psoriatic Arthritis (PsA) Treatment Market to achieve a remarkable US$ 15.6 Billion by 2028, - PharmiWeb.com - February 9th, 2024 [February 9th, 2024]
- Tremfya potential highlighted by industry analyst GlobalData - The Pharma Letter - May 31st, 2023 [May 31st, 2023]
- Stress Leads to Increased Risk of Depression, Anxiety for Psoriasis ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Janssen Announces Positive Results From Guselkumab Psoriatic ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Early Intervention with Secukinumab May Be Effective for Patients ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- VEGF-A Inhibition Downregulates Blood Vessel Area in Psoriasis - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Scratching the itch, Lynk Pharmaceuticals trialling ointment for ... - OutSourcing-Pharma.com - May 31st, 2023 [May 31st, 2023]
- Brepocitinib More Efficacious Than Placebo in Long-Term Psoriatic ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- For Patients With Birthmarks, Psychosocial Interventions Improved ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Robert Hariri, MD: Natural Killer Cell Therapy Shows Remarkable ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Nalbuphine ER Tablets Show Promise as Cough Therapy in ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Benefit of Empagliflozin in HFpEF Consistent Regardless of Diuretic ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- selectION reports results from SAD stage of si-544 Phase Ib trial - Clinical Trials Arena - May 31st, 2023 [May 31st, 2023]
- No Link Observed Between Gastrointestinal Tract Surgery and New ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Lynk doses first cohort in Phase Ib trial of psoriasis therapy - Clinical Trials Arena - May 30th, 2023 [May 30th, 2023]
- Metabolic Inflammation Contributes to Depression in Psoriatic Disease - Dermatology Times - May 30th, 2023 [May 30th, 2023]
- Encouraging Diversity and Inclusion for Patients With Psoriatic ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- The Weekly Roundup: May 22-26 - Dermatology Times - May 30th, 2023 [May 30th, 2023]
- Pediatric Psoriasis Market: A Study of the Industry's Key Applications ... - The Navajo Post - May 30th, 2023 [May 30th, 2023]
- Phototherapy Lamps Market are set to witness a CAGR of 5.8 ... - Digital Journal - May 30th, 2023 [May 30th, 2023]
- Celltrion seeks approval for Stelara biosimilar in EU - The Investor - May 30th, 2023 [May 30th, 2023]
- Peter Marinkovich, MD: FDA Approval of B-VEC Gene Therapy for ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Nick Stucky, MD, Phd: Implications for Media Influence on Minoxidil ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Tildrakizumab Linked With HRQOL Improvement in Psoriasis in a Real-World Setting - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- Clinical Utility of Deucravacitinib for the Management of Moderate to ... - Dove Medical Press - May 18th, 2023 [May 18th, 2023]
- Covid-19 and Psoriasis: Is there a link? - Dunya News - May 18th, 2023 [May 18th, 2023]
- Improvement Needed in Study Interventions to Better Skin Self ... - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- Reviva Pharmaceuticals Announces Intent to File an IND for Brilaroxazine in Psoriasis After Promising Preclinical Data - Marketscreener.com - May 18th, 2023 [May 18th, 2023]
- Adam Friedman, MD: Addressing Disparities in Care for Patients ... - MD Magazine - May 18th, 2023 [May 18th, 2023]
- Early-Infancy Meningitis Infection Linked With Increased Risk of ... - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- NOVN: Counting Down to PDUFA - Yahoo Finance - May 18th, 2023 [May 18th, 2023]
- Psoriatic Arthritis (PsA) Treatment Market is likely to register CAGR ... - Future Market Insights - May 18th, 2023 [May 18th, 2023]
- New campaign raises awareness of topical steroid withdrawal - Professional Beauty - May 18th, 2023 [May 18th, 2023]
- MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody sonelokimab in... - February 2nd, 2023 [February 2nd, 2023]
- EVELO BIOSCIENCES, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Other Events (form 8-K) -... - February 2nd, 2023 [February 2nd, 2023]
- 12 Ways to Treat Psoriasis at Home - Healthline - January 22nd, 2023 [January 22nd, 2023]
- DTC Advertising Of Prescription Drugs In The U.S. Often Promotes Products With Comparatively Low Therapeutic Value - Forbes - January 19th, 2023 [January 19th, 2023]
- Types of Psoriasis: Pictures, Symptoms and Treatments - Healthline - December 18th, 2022 [December 18th, 2022]
- Psoriasis Pathogenesis and Treatment - PMC - PubMed Central (PMC) - November 23rd, 2022 [November 23rd, 2022]
- Drug-Provoked Psoriasis: Is It Drug Induced or Drug Aggravated? - November 23rd, 2022 [November 23rd, 2022]
- Im a Dermatologist and These 7 Things Could Be Making Your Psoriasis Worse - Well+Good - October 19th, 2022 [October 19th, 2022]
- 'Worst time of the year for me to be covered in scabs': Amber Heard's Alleged Ex Cara Delevingne Revealed Her Psoriasis Struggle Made Kate Moss Scream... - October 19th, 2022 [October 19th, 2022]
- Psoriasis: What It Is, Symptoms, Causes, Types & Treatment - October 17th, 2022 [October 17th, 2022]
- What is psoriasis and which foods ease symptoms? - Evening Standard - October 17th, 2022 [October 17th, 2022]
- Chronic inflammatory diseases: what they are - Emergency Live International - October 17th, 2022 [October 17th, 2022]
- How remote care can deliver a step change in treatment for inflammatory skin conditions - PoliticsHome - October 17th, 2022 [October 17th, 2022]
- Probiotics Supplementation may Improve Symptoms of Hyperuricemia and Gout - Rheumatology Network - October 15th, 2022 [October 15th, 2022]
- Psoriasis Pathogenesis and Treatment - PubMed - October 2nd, 2022 [October 2nd, 2022]
- Best and Worst Drinks for Psoriasis - Everyday Health - October 2nd, 2022 [October 2nd, 2022]
- These Are the 10 Most Common Chronic Skin Conditionsand the Most Important Facts to Know About Them - Parade Magazine - October 2nd, 2022 [October 2nd, 2022]
- Survey Addresses Concerns Regarding Reproductive Healthcare Communication in Women with RA, PsA - Rheumatology Network - October 2nd, 2022 [October 2nd, 2022]
- Psoriasis Types, Symptoms & Causes | NIAMS - September 29th, 2022 [September 29th, 2022]
- What Is Psoriasis And Can It Be Treated? - Forbes - September 29th, 2022 [September 29th, 2022]
- Plaque Psoriasis Treated With Tildrakizumab Shown to be Effective in Real-World Settings - MD Magazine - September 29th, 2022 [September 29th, 2022]
- Alumis Announces Initiation of Patient Dosing in Phase 2 Clinical Trial of ESK-001 for the Treatment of Plaque Psoriasis - Business Wire - September 29th, 2022 [September 29th, 2022]
- 15 Items That Will Make Your Life With Psoriatic Arthritis Easier - BlackDoctor.Org - September 29th, 2022 [September 29th, 2022]
- MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody sonelokimab in patients with active psoriatic arthritis - BioSpace - September 27th, 2022 [September 27th, 2022]
- How diversity and inclusion continues to be incorporated in dermatology - PMLiVE - September 27th, 2022 [September 27th, 2022]
- Arcutis Announces Topline Results From ARRECTOR Pivotal Phase 3 Trial Of Roflumilast Foam 0.3% In Scalp A - Benzinga - September 27th, 2022 [September 27th, 2022]
- Psoriasis Treatment Market Size to Hit USD 51.24 Bn by 2030 - GlobeNewswire - August 15th, 2022 [August 15th, 2022]
- Ventyx Sees Initiation Of Mid-Stage Psoriasis Study In Q4 2022 Following Positive Data From Initial-Stage - Benzinga - August 15th, 2022 [August 15th, 2022]
- Woman, 29, Slams Bullies Who 'Giggle And Whisper' At Her Unsightly Psoriasis Sores And Scabs, Leaving Her Depressed And 'Struggling To Walk' -... - August 15th, 2022 [August 15th, 2022]